MARKET

ALPN

Alpine Immune Sc
ALPN
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-8.1917
66.59
12.80
4,456,781,329.19
Alpine Immune Sc: Securities to be offered to employees in employee benefit plans, post-effective amendments
Press release · 05/20 16:04
Weekly Report: what happened at ALPN last week (0513-0517)?
Weekly Report · 05/20 11:31
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. The company is developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. 11 analysts have recently evaluated Alpine Immune sciences and provided 12-month price targets. The average price target is $ and the company's revenue growth has faced challenges.
Benzinga · 05/16 13:00
Alpine Immune Sciences Price Target Maintained With a $65.00/Share by Wedbush
Dow Jones · 05/16 12:48
Wedbush Reiterates Neutral on Alpine Immune Sciences, Maintains $65 Price Target
Benzinga · 05/16 12:38
Analysts Offer Insights on Healthcare Companies: Eyenovia (EYEN), Alpine Immune Sciences (ALPN) and GoodRx Holdings (GDRX)
TipRanks · 05/16 12:20
ALPN Factor-Based Stock Analysis
NASDAQ · 05/15 20:12
XBI, ALPN, RVMD, IBRX: Large Outflows Detected at ETF
NASDAQ · 05/15 16:14
More

Webull offers Alpine Immune Sc stock information, including NASDAQ: ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.